Top Markets
#1 Black Phoenix Black Phoenix +829.59%
#2 pipedog pipedog +41.28%
#3 PondCoin PondCoin +35.42%
#4 Bless Bless +35.40%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.00%
#7 Beam Beam +24.62%
#8 Seeker Seeker +21.01%
#9 Magma Finance Magma Finance +20.64%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rank in Stocks #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Share Price
$64.97
Last synced: 2024-05-20
Market Cap
$1.97B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alpine Immune Sciences, Inc. (ALPN)

Category

Healthcare
P/S ratio for Alpine Immune Sciences, Inc. (ALPN)
P/S ratio as of August 2026 TTM: 75.70
According to Alpine Immune Sciences, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 75.70. At the end of 2022 the company had a P/S ratio of 8.17.
P/S ratio history for Alpine Immune Sciences, Inc. from 2012 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 75.70 367.56%
2023 16.19 98.02%
2022 8.17 -45.69%
2021 15.05 -46.46%
2020 28.11 -30.62%
2019 40.52 -43.96%
2018 72.29 72.38%
2017 41.94 256.51%
2016 11.76 -92.02%
2015 147.42 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -86.57%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -86.62%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -96.10%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -85.10%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH